You are here

  • Home
  • Archive
  • Volume 31, Issue 10
  • Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Article metrics

Article menu
Download PDFPDF
Clinical trial
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

 

Online download statistics by month:

Online download statistics by month: October 2021 to April 2024

AbstractFullPdf
Oct 202126323219
Nov 20215861718
Dec 202119477
Jan 202225767
Feb 2022414137
Mar 2022490911
Apr 202230723
May 202228646
Jun 20226423122
Jul 202236566
Aug 20224001514
Sep 202234290
Oct 2022333149
Nov 202229353
Dec 202238887
Jan 20231621310
Feb 202336468
Mar 202330123
Apr 202338697
May 202322453
Jun 202314000
Jul 2023260106
Aug 202313486
Sep 202317200
Oct 202312292
Nov 2023325166
Dec 202320063
Jan 202413821
Feb 2024226123
Mar 202419710
Apr 202414300
Total11423277197